Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439007 | 0.81 | CHRM1 (0.37) | RXFP1SMN1; SMN2 | |
| SCHEMBL10564226 | 0.79 | CHRNB2 (0.35) | RXFP1SMN1; SMN2 | |
| SCHEMBL3323695 | 0.79 | HPGD (0.34) | SMN1; SMN2HPGD | |
| SCHEMBL3256671 | 0.79 | HPGD (0.34) | SMN1; SMN2HPGD | |
| SCHEMBL12969435 | 0.77 | RXFP1 (0.33) | RXFP1SMN1; SMN2 | |
| SCHEMBL28554513 | 0.76 | AOC3 (0.33) | RXFP1 | |
| SCHEMBL19027654 | 0.76 | SMN1; SMN2 (0.32) | RXFP1SMN1; SMN2 | |
| SCHEMBL11006249 | 0.76 | RXFP1 (0.30) | RXFP1 | |
| SCHEMBL1550865 | 0.76 | ALDH1A1 (0.42) | RXFP1SMN1; SMN2 | |
| SCHEMBL9775766 | 0.76 | TRPA1 (0.32) | RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958862-B2 | Compounds and compositions and uses thereof | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-10927124-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190308990-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3494119-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10196403-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. | 2018-02-01 | — | — | US | disclosed |
| WO-2018023072-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196403-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | RXFP1 4303/4885SMN1; SMN2 94/4885HPGD 118/4885 |
| US-10927124-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | RXFP1 4303/4885SMN1; SMN2 94/4885HPGD 118/4885 |
| US-11958862-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | RXFP1 4303/4885SMN1; SMN2 94/4885HPGD 118/4885 |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | RXFP1 4303/4885SMN1; SMN2 94/4885HPGD 118/4885 |
| US-20190308990-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | RXFP1 4303/4885SMN1; SMN2 94/4885HPGD 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.